6 March 2024 - Despite the concerns of the biopharma industry, the Inflation Reduction Act has been enacted and with it, Medicare is allowed to negotiate the prices of drugs. 

It is believed that the IRA will save Medicare about $300 billion in drug costs in the coming decade – considerable savings for the government but also a considerable loss in revenues for industry. When one considers that biopharma invests 25% of top line revenues into R&D, these price negotiations, essentially price controls, will result in roughly $75 billion less devoted to drug discovery.

Read Forbes article